Breakthrough revelead in sickle cell treatment options
Sickle cell disease is a genetic condition that affects hundreds of thousands of people round the world. Health reporter Pauline Chan details the latest development in treatment options.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 hours ago
- Globe and Mail
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ending the month in positive territory. However, the two worst-performing Dow stocks in May -- both from the healthcare sector -- kept the index's rally in check, with one of them plunging over 25%. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » 1. UnitedHealth Group Shares of UnitedHealth Group (NYSE: UNH) crashed 26.6% in May after multiple negative developments sent shockwaves through the investing community. In mid-May, UnitedHealth suddenly replaced its CEO, Andrew Witty, with former CEO Stephen J. Hemsley with immediate effect and suspended its earnings outlook for the full year because of a surge in medical costs. In between, The Wall Street Journal reported a criminal investigation against UnitedHealth by the Department of Justice for a "possible medicare fraud." Days later, The Guardian released a scathing report alleging UnitedHealth put patients' health at risk by paying secret bonuses to nursing homes to cut hospital transfers. For now, UnitedHealth expects to "return to growth" in 2026 and has sued The Guardian for defamation. Regaining investor confidence, however, may not be easy. The stock is down 38% so far this year, as of this writing. 2. Merck Merck (NYSE: MRK) stock lost 9.8% in May and plunged to its 52-week low of $73.31 a share after President Donald Trump signed an executive order directing drugmakers in the U.S. to cut the prices of prescription drugs. This comes at a time when Merck already expects tariffs to add $200 million to its costs this year. Investors are also worried about Merck's future once its blockbuster oncology drug Keytruda loses patent exclusivity. In mid-May, analysts at Citi slashed Merck stock's price target to $84 per share from $115 per share citing the pharmaceutical company's growth challenges and a "lack of urgency" to develop a business that could soften the impact of a potential loss of up to 20% of sales for Keytruda once its patent expires. Merck, however, has a strong pipeline, remains committed to dividend growth, and yields 3.9%. Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
CTV News
5 hours ago
- CTV News
Alberta limiting free access to COVID-19 vaccines
Alberta has announced COVID-19 vaccines will only be provided for free to certain members of the population starting this fall.
CTV News
6 hours ago
- CTV News
‘Really interesting project': P.E.I. researcher studying genetic mutation linked to Parkinson's
The Atlantic Veterinary College (AVC) in Charlottetown is best known for its veterinary medicine program, but it's also home to scientific research on human health. It's in the planning stages now, but later in the summer research will officially begin at the AVC into Parkinson's disease, thanks to a three-year grant from Parkinson Canada. 'Being able to get an award like this and get funded to do this research is not easy,' says Dr. Jay Penney, who was awarded the $135,000 grant following an application. 'I'm certainly quite happy. It's allowing me to do this research, which will hopefully lead to helping people with Parkinsons.' Penney is an associate professor and Canada Research Chair at Biomedical Genetics at the AVC. The funding will be used to examine a newly-discovered mutation of the RAB32 gene, which is linked to Parkinson's disease. 'There's been quite a few of those mutations identified over the years, but this particular one was just found last summer, so it's quite newly-identified,' explains Penney. 'Basically, this research is designed to try to understand what's happening at the cellular level in the cells of the brain that is being caused by this mutation.' In his lab, Penney and his team will use human stem cell models to create brain cells that contain the mutation and study them. While the money won't be in place until the end of the summer, Penney is currently in the planning stages of his work. He plans on looking at different cellular signaling pathways and processes and try to test whether those are altered. 'The stem cell models that Jay is using is helpful because he's using actual human cells from Parkinson's patients,' says Ko Currie, the manager for research funding and partnerships manager with Parkinson Canada. 'It's really one of the closest model symptoms there are to studying Parkinson's in human patients.' According to Parkinson Canada, more than 110,000 people in Canada are living with the neurodegenerative disorder. Currie says Canada 'punches above its weight' when it comes to Parkinson's research. 'We have some of the most well-renowned doctors and research scientists in the world,' adds Currie. 'So, we have a really strong research program for Parkinson's disease.' Currie and Penney hope the work in Prince Edward Island will help the medical community understand more about the disease. 'The whole project is aimed at trying to understand what this mutation does to the cells of the brain,' adds Penney. 'It's pretty early stages of basic science research, which is aimed to try to understand what's happening. And then once we understand what's happening, we have a lot better chance of figuring out how to fix it.' The funding for the study will be available beginning in August. 'The better we understand Parkinson's, the more targets we have, the better we'll be set up for designing new therapies, new drugs, to ultimately stop Parkinson's at the end of the day,' says Currie. For more P.E.I. news, visit our dedicated provincial page.
